These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1047 related articles for article (PubMed ID: 17332899)

  • 1. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2008; 21(1):36-43. PubMed ID: 18301808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling type I error rate for fast track drug development programmes.
    Shih WJ; Ouyang P; Quan H; Lin Y; Michiels B; Bijnens L
    Stat Med; 2003 Mar; 22(5):665-75. PubMed ID: 12587098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerating drug development and approval.
    Cole P
    Drug News Perspect; 2010; 23(1):37-47. PubMed ID: 20155218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orphan drug development in the United States.
    Groft SC
    CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
    Robinson WT
    Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ
    Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
    [No Abstract]   [Full Text] [Related]  

  • 16. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 53.